ImmunityBio announced $100 million in financing transactions, including $75 million in non-dilutive funding, aimed at strengthening its balance sheet and supporting global expansion and advancement of its broader immunotherapy pipeline.
The $75 million in non-dilutive capital comes under an existing Royalty Interest Purchase Agreement with Oberland Capital, increasing the total committed capital under the agreement to $375 million. The updated agreement retains its core terms, with a modest increase in the royalty payback rate while maintaining the royalty cap.
In a parallel move, Nant Capital, an entity affiliated with the company’s executive chairman, converted $25 million of outstanding debt into equity through the issuance of 4.6 million shares. This transaction reduces debt tied to a $505 million promissory note issued in December 2024 and further strengthens the company’s balance sheet.
The company said the proceeds will support continued scaling of commercial operations and international expansion following recent regulatory approvals, while also advancing its immunotherapy pipeline.
ImmunityBio has recently expanded the global footprint of its lead therapy, ANKTIVA, which is now approved or authorized across approximately 34 countries, including the United States, United Kingdom, European Union, Saudi Arabia, and Macau. The therapy is used in combination with BCG for bladder cancer and has also received authorization in Saudi Arabia for lung cancer in combination with checkpoint inhibitors.
ANKTIVA is designed to activate key immune cells, including natural killer cells and CD8+ T cells, by leveraging interleukin-15 biology to enhance the immune system’s ability to target cancer cells and generate lasting immune memory.
The company continues to position its Cancer BioShield platform as a core strategy, combining cytokine-based therapies, cell therapies, and vaccine approaches to stimulate both innate and adaptive immune responses while potentially reducing reliance on traditional chemotherapy and radiation.
KEY QUOTES
“This additional non-dilutive financing gives us the capacity to continue scaling our commercial efforts and expanding globally following recent ANKTIVA approvals, while positioning us to take full advantage of the growth opportunities ahead. The strengthening of the company’s balance sheet through non-dilutive financing from Oberland, combined with the Founder’s reduction of debt, supports our global expansion following recent approvals and the advancement of our immunotherapy pipeline.”
Richard Adcock, President And CEO, ImmunityBio
“The non-dilutive financing from Oberland and the conversion of debt to equity by Nant Capital, reflect strong confidence in ImmunityBio’s strategy and growth potential as a leading immunotherapy company paving the way for next-generation immunotherapy treatments.”
Patrick Soon-Shiong, Founder, Executive Chairman And Global Chief Medical And Scientific Officer, ImmunityBio
